Cover Image

Device-Aided Therapies in Parkinson's Disease /

This volume, 'Device-Aided Therapies in Parkinson's Disease,' is a comprehensive resource on the latest advancements in the treatment of Parkinson's Disease, focusing on device-aided therapies. Edited by experts in the field, it covers topics such as continuous dopaminergic stimu...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Odin, P. (Per) (Editor), Chaudhuri, K. Ray (Editor), Falup-Pecurariu, Cristian (Editor)
Format: eBook
Language:English
Published: London, England : Academic Press, [2024]
Edition:First edition.
Series:International Review of Movement Disorders Series.
Subjects:
Parkinson's disease > Treatment.
Maladie de Parkinson > Traitement.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Intro
  • Device-Aided Therapies in Parkinson's Disease
  • Copyright
  • Contents
  • Contributors
  • Preface
  • Chapter One: Continuous dopaminergic stimulation and the transition to using continuous drug delivery in Parkinson´s dise ...
  • 1. Introduction
  • 2. Background
  • 3. Is CDS as straight forward as we think?
  • 4. Moving to continuous drug delivery
  • 4.1. Continuous drug delivery-The future
  • References
  • Chapter Two: Apomorphine infusion in Parkinson´s disease: An update
  • 1. Introduction
  • 2. Background and development
  • 3. Recent trial data
  • 4. Key motor effects
  • 5. Key non-motor effects
  • 6. Quality of life data
  • 7. Side effects and safety
  • 8. Conclusions and future perspectives
  • References
  • Chapter Three: Levodopa-carbidopa intestinal gel infusion in Parkinson´s disease
  • 1. Introduction
  • 1.1. Background and development
  • 1.2. Patient selection for levodopa infusion
  • 1.3. The technical side of the treatment
  • 1.4. Practical aspects of LCIG therapy
  • 1.5. Profile of plasma levodopa concentration over time
  • 2. Clinical outcomes of levodopa infusion
  • 3. Clinical outcome: Key motor effects
  • 3.1. Effect on motor symptoms
  • 3.2. Effect on dyskinesia
  • 3.3. Effect on tremor
  • 3.4. Effect on freezing of gait
  • 4. Clinical outcome: Key non-motor effects
  • 4.1. Effect on non-motor symptoms
  • 5. Clinical outcome: Quality of life data
  • 5.1. Effect on quality of life
  • 6. Side effects and safety
  • 6.1. Surgery
  • 6.2. Pump and tubing
  • 6.3. Pharmacological side effects and polyneuropathy
  • 6.4. Continuous drug delivery and impulse control disorders
  • 7. Miscellaneous
  • 7.1. Discontinuation of LCIG pump therapy
  • 7.2. Cost of advanced treatments
  • 8. Conclusion
  • References
  • Chapter Four: Levodopa-entacapone-carbidopa intestinal gel infusion in Parkinson´s disease
  • 1. Introduction.
  • 2. Background and development
  • 3. Trial data
  • 4. Key motor effects
  • 5. Key non motor effects
  • 6. Quality of life data
  • 7. Side effects and safety
  • 8. Conclusions
  • References
  • Chapter Five: Subcutaneous foslevodopa/foscarbidopa: A novel 24h delivery option for levodopa
  • 1. Introduction
  • 1.1. The need for non oral levodopa based therapies
  • 1.1.1. Non oral levodopa therapy and 24h treatment
  • 1.1.2. Non oral levodopa based continuous drug delivery systems
  • 2. Subcutaneous foslevodopa and foscarbidopa
  • 3. Pharmacokinetics
  • 4. Clinical trials
  • 5. Foslevodopa/foscarbidopa specific effects: Early morning off related akinesia (EMO) and effect on sleep
  • 6. Nocturia
  • 7. Cost benefit analysis
  • 8. Safety
  • 9. Conclusions
  • Acknowledgments
  • Declaration of competing interest
  • CRediT authorship contribution statement
  • References
  • Further reading
  • Chapter Six: Subthalamic deep brain stimulation surgery for Parkinson´s disease
  • 1. Introduction
  • 2. Key landmark articles on STN-DBS for PD
  • 3. Motor effects of STN-DBS in PD
  • 3.1. Tremor
  • 3.2. Rigidity
  • 3.3. Bradykinesia
  • 3.4. Motor fluctuations and dyskinesias
  • 3.5. Axial symptoms
  • 3.6. Medication adjustments
  • 3.7. Short-term motor effects
  • 3.8. Long-term motor effects
  • 3.9. Study type and critical insights
  • 4. Effect of STN-DBS on non-motor symptoms
  • 4.1. Cognitive functions
  • 4.2. Mood and psychiatric effects
  • 4.3. Sleep disorders
  • 4.4. Autonomic dysfunction
  • 5. Effects of STN-DBS on quality of life
  • 5.1. Short-term benefits on quality of life
  • 5.1.1. Immediate improvements in daily functioning
  • 5.1.2. Reduction in medication burden
  • 5.1.3. Psychological well-being
  • 5.2. Long-term benefits on quality of life
  • 5.2.1. Sustained motor benefits
  • 5.2.2. Adaptation and acceptance.
  • 5.2.3. Cognitive and psychiatric considerations
  • 6. Safety, tolerability, and limitations of STN-DBS
  • 6.1. Short-term safety and tolerability
  • 6.1.1. Surgical risks
  • 6.1.2. Acute neurological effects
  • 6.2. Long-term safety, adverse effects, and limitations
  • 6.2.1. Device-related complications
  • 6.2.2. Neuropsychiatric effects
  • 6.2.3. Motor and non-motor symptoms progression
  • 6.2.4. Adverse effects on speech
  • 6.2.5. Gait and balance effects
  • 7. Future of STN-DBS
  • 8. Conclusion
  • References
  • Chapter Seven: Globus pallidus internus deep brain stimulation in the management of movement disorders: Current evidence ...
  • 1. Introduction and background
  • 1.1. Brief History of pallidal surgery in movement disorders
  • 1.2. Embryology, neurophysiology, and age-dependent developmental plasticity of the GPi
  • 1.3. Neuroimaging, surgical procedure, and current technologies in GPi-DBS
  • 1.3.1. Neuroimaging
  • 1.3.2. Surgical procedure
  • 1.3.3. Current and upcoming technologies
  • 1.4. Multidisciplinary team approach
  • 1.5. Ethical considerations
  • 2. GPi DBS for Parkinson´s disease
  • 2.1. Clinical features and pathophysiology of Parkinson´s disease
  • 2.2. Indications and selection criteria for GPi-DBS in Parkinson´s disease
  • 2.3. Connectivity and working mechanisms of GPi-DBS in Parkinson´s disease
  • 2.4. Clinical trials and outcome
  • 3. GPI DBS in non-PD conditions
  • 3.1. Dystonia
  • 3.2. Tourette´s syndrome (TS)
  • 3.3. Aggressive behavior and self-harm
  • 4. Perspectives and conclusion
  • Financial support
  • Conflict of interest statement
  • References
  • Chapter Eight: Treating Parkinson´s disease and movement disorders with transcranial focused ultrasound
  • 1. Introduction
  • 2. Technical and medical fundamentals
  • 2.1. Focused ultrasound for treating for brain diseases.
  • 2.2. The technical implementation of the MRgFUS technology
  • 3. Clinical results of MRgFUS-treatment
  • 3.1. Essential tremor and other tremors
  • 3.1.1. The surgical target for essential tremor
  • 3.1.2. Results of unilateral treatment
  • 3.1.3. Uncontrolled studies and case series
  • 3.1.4. Bilateral MRgFUS for essential tremor
  • 3.1.5. Other action/intention tremors or dystonia
  • 3.2. Parkinson´s disease
  • 3.2.1. Vim-MRgFUS for Parkinsonian tremor
  • 3.2.2. STN-MRgFUS for all motor symptoms of PD
  • 3.2.3. MRgFUS of the Gpi and the pallidothalamic tract for all motor symptoms of PD
  • 3.3. Other indications
  • 4. Conclusions
  • References
  • Chapter Nine: Patient selection for device aided therapies
  • 1. Introduction
  • 2. When to consider device-aided therapies (DAT)
  • 3. Available device aided therapies (DAT)
  • 3.1. Levodopa-carbidopa intestinal gel (LCIG)
  • 3.2. Continuous subcutaneous apomorphine infusion (CSAI)
  • 3.3. Deep brain stimulation (DBS)
  • 3.4. Levodopa-entacapone-carbidopa intestinal gel (LECIG)
  • 3.5. Foslevodopa/foscarbidopa subcutaneous infusion
  • 4. Tools for patient selection for DAT
  • 4.1. Identifying advanced PD patients-CEPA-study
  • 4.2. Navigate-PD
  • 4.2.1. Recognizing patients in need of DAT
  • 4.2.2. Age-related factors
  • 4.2.3. Motor symptoms and DAT
  • 4.2.4. Non-motor symptoms and DAT
  • 4.3. The Delphi Panel Consensus
  • 4.4. MANAGE-PD tool (``Making informed decisions to aid timely management of Parkinson´s disease)
  • 5. Patient selection for newer DAT
  • 5.1. Levodopa-entacapone-carbidopa intestinal gel (LECIG)
  • 5.2. Foslevodopa/Foscarbidopa Subcutaneous Infusion (PRODUODOPA)
  • 6. Optimizing compliance
  • 7. Conclusion
  • References
  • Chapter Ten: The future: Stem cells? Current clinical trials using stem cells for dopaminergic cell replacement
  • 1. Introduction.